The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

CRISPR–Cas9 genome editing technology is a promising tool for genetically engineering
immune cells and modulating immune systems. Although ex vivo genome editing of immune …

CRISPR-mediated genome editing of primary human lymphocytes is typically carried out via
electroporation, which can be cytotoxic, cumbersome and costly. Here we show that the …

Clustered regularly interspaced short palindromic repeats/associated protein 9
(CRISPR/Cas9) gene‐editing technology shows promise for manipulating single or multiple …

Despite the potential of small molecules and recombinant proteins to enhance the efficiency
of homology-directed repair (HDR), single-stranded DNA (ssDNA) donors, as currently …

Aquaporin-4 (AQP4)-specific Th17 cells are thought to have a central role in neuromyelitis
optica (NMO) pathogenesis. When modeling NMO, only AQP4-reactive Th17 cells from …

Adeno-associated virus (AAV) has emerged as the most promising vector for in vivo human
gene therapy, with several therapeutic approvals in the last few years and countless more …

Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious
treatment modality for refractory and relapsed hematopoietic malignancies in recent years …

Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, often fatal immune
deficiency characterized by severe systemic hyperinflammation. Although allogeneic bone …

One of the biggest challenges for in vivo gene therapy are vectors mediating highly selective
gene transfer into a defined population of therapy-relevant cells. Here we present DARPin …